Youcare Pharmaceutical Group's (688658.SH) Subsidiary Receives FDA Approval for YKYY018 Inhalation Clinical Trial

Stock News11-27

Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for the clinical trial of YKYY018 inhalation solution for the prevention and treatment of respiratory syncytial virus (RSV) infection (IND No.: 178457).

YKYY018 inhalation solution is an internationally original membrane fusion inhibitor independently developed by Youcare Kechuang using a full-process AI platform. The product features a novel mechanism of action, specifically binding to the heptad repeat region 1 (HR1) of the RSV fusion protein (F protein) F1 subunit. This inhibits the formation of the homologous 6-HB structure between the virus's HR1 and HR2 domains, blocking the fusion process between the virus and host cells to achieve antiviral effects. The drug offers both therapeutic and preventive functions.

The company has secured core patent rights for the product and holds exclusive global rights to its development and commercialization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161185543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161185543","market":"us","top_or_hot":-1,"title":"Youcare Pharmaceutical Group's (688658.SH) Subsidiary Receives FDA Approval for YKYY018 Inhalation Clinical Trial","media":"Stock News","content":"<p>Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for the clinical trial of YKYY018 inhalation solution for the prevention and treatment of respiratory syncytial virus (RSV) infection (IND No.: 178457).</p>\n<p>YKYY018 inhalation solution is an internationally original membrane fusion inhibitor independently developed by Youcare Kechuang using a full-process AI platform. The product features a novel mechanism of action, specifically binding to the heptad repeat region 1 (HR1) of the RSV fusion protein (F protein) F1 subunit. This inhibits the formation of the homologous 6-HB structure between the virus's HR1 and HR2 domains, blocking the fusion process between the virus and host cells to achieve antiviral effects. The drug offers both therapeutic and preventive functions.</p>\n<p>The company has secured core patent rights for the product and holds exclusive global rights to its development and commercialization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Youcare Pharmaceutical Group's (688658.SH) Subsidiary Receives FDA Approval for YKYY018 Inhalation Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYoucare Pharmaceutical Group's (688658.SH) Subsidiary Receives FDA Approval for YKYY018 Inhalation Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for the clinical trial of YKYY018 inhalation solution for the prevention and treatment of respiratory syncytial virus (RSV) infection (IND No.: 178457).</p>\n<p>YKYY018 inhalation solution is an internationally original membrane fusion inhibitor independently developed by Youcare Kechuang using a full-process AI platform. The product features a novel mechanism of action, specifically binding to the heptad repeat region 1 (HR1) of the RSV fusion protein (F protein) F1 subunit. This inhibits the formation of the homologous 6-HB structure between the virus's HR1 and HR2 domains, blocking the fusion process between the virus and host cells to achieve antiviral effects. The drug offers both therapeutic and preventive functions.</p>\n<p>The company has secured core patent rights for the product and holds exclusive global rights to its development and commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1161185543","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161185543","pubTimestamp":1764231017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has received a Study May Proceed Letter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"优康药业集团（688658.SH）子公司YKYY018吸入剂临床试验获FDA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"Youcare Pharmaceutical Group Co., Ltd. (688658.SH) announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for the clinical trial of YKYY018 inhalation solution for the prevention and treatment of respiratory syncytial virus (RSV) infection (IND No.: 178457).\nYKYY018 inhalation solution is an internationally original membrane fusion inhibitor independently developed by Youcare Kechuang using a full-process AI platform. The product features a novel mechanism of action, specifically binding to the heptad repeat region 1 (HR1) of the RSV fusion protein (F protein) F1 subunit. This inhibits the formation of the homologous 6-HB structure between the virus's HR1 and HR2 domains, blocking the fusion process between the virus and host cells to achieve antiviral effects. The drug offers both therapeutic and preventive functions.\nThe company has secured core patent rights for the product and holds exclusive global rights to its development and commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161185543","isCrawlerRequest":true}